Skip to main content
Premium Trial:

Request an Annual Quote

BioMérieux, Sysmex Dissolve Japanese Joint Venture

NEW YORK (GenomeWeb) – BioMérieux and Sysmex announced today that they will dissolve a nearly 10-year-old joint venture that aimed to bring BioMérieux's in vitro diagnostic products to the Japanese market.

No reason was given for the dissolution.

In early 2008, the companies formed the JV, called Sysmex BioMérieux, to promote and commercialize BioMérieux's IVD reagents and medical instruments in Japan through Sysmex's sales and marketing infrastructure. Sysmex held a 34 percent stake in the JV, with BioMérieux owning the remaining 66 percent.

However, the companies have now agreed to dissolve the JV, transferring all of Sysmex's holdings in the company to BioMérieux. Sysmex will continue to distribute BioMérieux products in Japan until Oct. 31 and provide customer service for these products until March 31, 2018. BioMérieux said that it intends to build its own commercial structure in Japan to take over activities previously handled by Sysmex.

Additional terms were not disclosed.

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.